DiaMedica Therapeutics Inc. DMAC NASDAQ

DiaMedica Therapeutics Inc. (DMAC) reported total assets of $61.37M and total liabilities of $5.26M for fiscal year 2025, resulting in total equity of $56.11M.

The company held $59.89M in cash and short-term investments. Total debt stood at $240K, with net debt of $-15.41M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 11.81, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 11.81 — balance sheet is strong
• MOAT (28/100) — Total assets $61.37M and equity $56.11M support the company's competitive scale
• VALUE (75/100) — Debt-to-Equity 0 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

CNTA

Centessa Pharmaceuticals plc

$39.61

+0.05%

TERN

Terns Pharmaceuticals, Inc.

$52.71

+0.06%

DAWN

Day One Biopharmaceuticals, Inc.

$21.47

+0.05%

IOVA

Iovance Biotherapeutics, Inc.

$3.82

+4.95%

LIFE

aTyr Pharma, Inc.

$14.77

+0.54%

SCPH

scPharmaceuticals Inc.

$5.67

+0.00%

MIST

Milestone Pharmaceuticals Inc.

$2.20

+8.37%

IKT

Inhibikase Therapeutics, Inc.

$1.79

+5.29%